Abstract
Numerous important chemotherapeutic agents are non-ribosomal peptides (NRPs). Synthesised as secondary metabolites, they include a range of antimicrobials and recent work examining the biosynthetic pathways of non-ribosomal peptides suggests that the paths may be manipulated at a molecular genetic level. This provides a fantastic opportunity for the rapid and cost-effective discovery of novel antibiotic agents.